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Abstract 
Background: Proliferation of large granular lymphocytes (LGL) and T cell-LGL (T-LGL) in 
peripheral blood along with demonstration of clonality are the hallmarks of a 
heterogeneous group of disorders, including T-LGL leukemia or T-LGL lymphocytosis. They 
are often associated with neutropenia and responsive to immunosuppression. The true 
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nature of this entity is not well understood. Some cases are reported as reactive 
phenomena with very limited experience in pediatric population.  
Methods: Hematology/Oncology Flow Cytometry Laboratory database has been reviewed 
retrospectively. Patients with identifiable distinct CD5-dim T cell population and positive 
clonal T-cell receptor (TCR) rearrangement were included in the analysis. Clinical and 
laboratory data were then reviewed.  
Results: Sixteen cases of children and young adults with increased peripheral blood clonal T-
LGL population characterized by dim CD5 expression with wide range of underlying immune 
dysregulation/stimulation disorders were reviewed. Extended follow up with repeat testing 
suggested the reactive nature of persistent clonal T-LGL proliferations in this group.  
Conclusions: Our observations indicate that clonal T-LGL proliferations in children and 
young adults are reactive in nature and some can be persistent with an indolent course with 
unknown consequentiality. Clonal T-LGL cells could be targeting the most prominent 
immunogenic stressor(s) involved as a control mechanism. 
Introduction 
Clonal T-cell large granular lymphocyte (T-LGL) proliferations, also named as T-LGL leukemia 
or T-LGL lymphocytosis are a heterogeneous group of disorders characterized by presence 
of clonal T-LGL cells for more than 6 months and usually, but not always a population size of 
minimum 2x109/L in peripheral blood. Clinically, such patients frequently have immune-
mediated cytopenias, particularly neutropenia in addition to increase in T-LGL cells with a 
clonal pattern in peripheral blood [1]. Proliferating T-LGL cells are characterized by CD3, 
CD5-dim, predominantly CD8, and T cell receptor (TCR)-alpha/beta expression on flow 
cytometry. Various T-LGL proliferations have number described in aplastic anemia, pure red 
cell aplasia, celiac disease, hypoplastic myelodysplastic syndrome, paroxysmal nocturnal 
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hemoglobinuria, dasatinib therapy, lymphomas, solid organ recipients and Felty syndrome 
[2,3,4,5,6].  
The pathophysiology of clonal T-LGL proliferations is yet to be explained. The distinction 
between reactive and malignant entities is not well-defined. This proliferation, at times, was 
labeled as “T-cell clonopathy of undetermined significance” previously and potential unclear 
nature of T-LGL proliferations has been addressed recently [6,7]. Determination of clonality 
has been often seen as an indicator of a leukemic process. Thus, these cases are often 
considered as T-LGL leukemia. Recently, acquired STAT3 mutations are proposed as an 
additional evidence for malignant process in large granular lymphocyte (LGL) leukemia [8]. 
And STAT3 mutations have been recently reported in 43% of clonal T-LGL proliferations in 
patients with Felty syndrome [9]. Successful use of immunosuppressive agents in LGL 
leukemia treatment without intensive chemotherapy regimens otherwise used in the 
treatment of various types of leukemia indicate an indolent course. The experience on this 
entity is much more limited in the pediatric population. In this study, we review our 
observations and findings in clonal T-LGL proliferations in children and young adults.  
Methods 
Patients 
We retrospectively reviewed Hematology/Oncology Flow Cytometry Laboratory database in 
an Institutional Review Board at Wayne State University-approved study. Cases with the 
presence of identifiable separate CD5-dim T cell populations in conjunction with positive 
clonal T-cell receptor (TCR) rearrangement patterns were included in the analysis. In the 
majority of the cases, flow cytometric determination of increased CD5-dim T cell expansion 
preceded the first TCR rearrangement testing. Many patients have had repeated flow 
cytometric analysis and TCR rearrangement testing, while four patients had just one TCR 
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rearrangement testing. Clinical histories, complete blood count, TCR rearrangement and 
lymphocyte subset analysis results were reviewed.  
Flow cytometric analysis and peripheral blood lymphocyte morphology 
Mononuclear cells from heparinized peripheral blood (PB) samples were obtained by 
density gradient separation using Fico/Lite-LymphoH (Atlanta Biologicals; Flowery Branch, 
GA), washed in complete medium (RPMI1640+10% fetal bovine serum (FBS)+gentamycin) 
and re-suspended in phosphate-buffered saline (PBS)+30% adult bovine serum as a blocking 
agent for non-specific staining of immunoglobulins.  Surface markers were assessed for 3-
color immunophenotyping by incubating mononuclear cells for 20 minutes in the dark with 
fluorescence-conjugated monoclonal antibodies CD3-PC5, CD19-FITC, CD5-PE and CD3-PC5, 
CD57-FITC, CD8-PE (Beckman Coulter; Brea, CA), followed by washing in PBS and 
resuspension in PBS + 0.4% formaldehyde as a fixative prior to acquisition using a Coulter 
XL-MCL flow cytometer (Beckman Coulter; Brea, CA) equipped with an Argon laser.  
In 4 recent cases, 10-color immunophenotyping was performed using a Coulter Gallios flow 
cytometer (Beckman Coulter; Brea, CA). Surface markers were assessed with fluorescence-
conjugated monoclonal antibodies for CD3, CD4, CD5, CD8, CD16, CD19, CD45, CD56, CD57 
and TCR-αβ. Mature T-lymphocytes were analyzed using Boolean gating around the CD3-
bright lymphocyte population. Isotype and/or FMO controls were used to assign background 
staining and to allow determination of percent reactivity with tested antibodies. T-LGL 
populations have a distinctive dim CD5-positive profile among mature T-cells.  A total of 
fifty-seven PB flow cytometry tests obtained for clinical indications in those 16 cases were 
analyzed. Wright-Giemsa-stained PB smears were prepared from EDTA anticoagulated blood 
and reviewed under microscope for lymphocyte morphology and detection of large granular 
lymphocytes.  
 
This article is protected by copyright. All rights reserved. 
T cell receptor (TCR) gene rearrangement analysis 
Genomic DNA isolation and T-cell clonality testing were performed at the Detroit Medical 
Center University Laboratories Molecular Genetics Laboratory, a CLIA-licensed and College 
of American Pathologist accredited laboratory (Detroit, MI). Genomic DNA was extracted 
from peripheral blood white blood cells with the Gentra Puregene DNA isolation kit (Qiagen, 
Venlo, Netherlands) according to the manufacturer’s recommendations. Two hundred and 
fifty nanograms of genomic DNA was amplified with the TCR Beta Gene Clonality Assay and 
TCR Gamma Gene Rearrangement Assay 2.0 ABI Fluorescence Detection kits (Invivoscribe, 
San Diego, California) targeting V, D, and J regions that flank the unique hypervariable 
antigen-binding region 3 (CDR3) of the TCR-beta and V and J regions of the TCR-gamma gene 
loci, respectively, according to manufacturer’s and the Euroclonality/Biomed-2 consortium 
recommendations. PCR products were analyzed by capillary electrophoresis using an ABI 
3130xl genetic analyzer and GeneMapper v4.0 software (Applied Biosystems, Foster City, 
California). A clonal pattern was defined as the presence of one or two peaks that are at 
least 3 times the height of the polyclonal background. When a clonal pattern was detected 
in a single multiplex PCR reaction, testing was repeated to exclude pseudo-clonality. 
Results 
Sixteen cases of clonal T-LGL proliferation included in this analysis had a wide spectrum of 
underlying conditions, three of which were in the young adult age category. Cases have been 
followed up to 7 years. None of the cases had neutropenia as part of their spectrum in 
contrast to frequent association with T-LGL leukemia in the literature. Three patients had 
chronic graft versus host disease (cGvHD), 2 Evans syndrome (ES) *10+, and one case for each 
of the following conditions: common variable immunodeficiency disorder (CVID), severe 
combined immunodeficiency (SCID) with maternal engraftment who developed 
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cytomegalovirus infection following umbilical cord blood transplantation (UCBT) and later 
acute Epstein-Barr virus (EBV) infection *11+, co-existing Langerhans cell histiocytosis (LCH) 
and primary hemophagocytic lymphohistiocytosis (HLH) *12+, autoimmune hemolytic 
anemia, chronic idiopathic thrombocytopenic thrombocytopenia (cHL), Hodgkin lymphoma 
(HL), X-linked lymphoproliferative disorder, Rosai-Dorfman disease (RDD), acute EBV 
infection, acute parvovirus B19 infection and paroxysmal nocturnal hemoglobinuria with 
history of treated severe aplastic anemia (Table1). Pathophysiological processes involved in 
these cases included various combinations of inherited immune deficiency in 4, acquired 
immune deficiency in 5, lymphoproliferation in 6, alloimmune reaction in 3, autoimmune 
reaction in 5, infection in 4, inflammation in 3 and malignancy in 1 case. 
One patient (case #3) with SCID had three different clonal peaks at different times in 
association with maternal engraftment, CMV infection following UCBT and during an acute 
EBV infection after immune suppression withdrawal, respectively *11+. The patient with RDD 
(case #11) developed clonal T-LGL expansion when his disease flared. In three instances in 
two patients, clonal T-LGL proliferations disappeared with the resolution of underlying 
disease, acute EBV infection in case #13, maternal engraftment and CMV infection in case 
#3, respectively. However, the T-LGL clones persisted and were frequently associated with 
relative increased presence over time, if the disease process continued to be active or 
progressed, despite the use of therapeutic approaches including several lines of either single 
or combined immunosuppressive medications (Figure1). In summary, three clonal T-LGL 
proliferations in 2 patients have resolved, were persistent in 9 with the original TCR 
rearrangement pattern, and 4 cases have not been reevaluated (Table 1 and Table 2). 
Among the cases with persistent clonal T-LGL proliferation lasting longer than 6 months, 
three patients, cases #3, #12 and #14 had active cGvHD following allogeneic hematopoietic 
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stem cell transplantation. They were on various immunosuppressive treatment regimens 
and had persistent clonal T-LGL proliferations lasting 23, 18 and 21 months, respectively. 
Cases #5 and #6 with Evans syndrome has been followed for several years and have been on 
various immune suppressive regimens throughout their course and had clonal T-LGL lasting 
26 and 24 months, respectively. Case #1 was referred to us for splenomegaly and was found 
to have panhypogammaglobulinemia and diagnosed with CVID and further investigation 
revealed double heterozygous TACI mutation as the cause. A repeat set of tests in 8 months, 
demonstrated continued clonal T-LGL proliferation while on intravenous immunoglobulin 
supplementation. Case #4 was diagnosed with concurrent primary HLH and LCH when the 
patient presented with fever, hepatosplenomegaly and cytopenias and responded to 
chemotherapy directed to LCH. Studies performed following completion of treatment 
revealed clonal T-LGL proliferation, which has lasted for 56 months.  
Case #8 with cITP on immunosuppressive treatment was tested twice 9 months apart with 
positive clonal T-LGL proliferation. Case #9 had HL and underwent successful chemotherapy 
and continued to have clonal T-LGL proliferation for 11 months. None of our patients had T-
LGL populations greater than 2x109/L, which is debated not be a pre-requisite for diagnosis 
of T-LGL leukemia, despite significant percent presence in the lymphocyte population. This 
could be partially due to clinical symptoms, such as splenomegaly and/or treatment of the 
underlying disease with steroids or chemotherapy leading to lymphopenia. 
The size of the CD5-dim T cell population was variable with a median value of 18.6% and as 
high as 58.7% of the lymphocyte population. Presence of T-LGL population has positively 
correlated with CD8, CD57 and inversely with CD19 expression (all P=0.001). Furthermore, 
10-color analysis of CD5dim+ T cell population performed on 10-color Gallios Flow 
Cytometer, showed predominance of CD8, TCR-, and CD57-positive subsets with an 
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average of 69.6% (51.5 – 78.8) CD8-positive, 79.6% (60.3 – 94.1) TCR--positive and 45.5% 
(10.8 – 60.6) CD8/CD57 double-positive cells, whereas CD4-positive cells constituted 13% 
(2.8 – 23.1) and CD56/CD16 double-positive cells 4.1% (1.1 – 5.9) in 4 cases studied (Figure 
2).  
Discussion  
There have been many reported cases of T-LGL leukemia associated with underlying 
autoimmune disorders, malignancy, bone marrow failure, solid organ transplantation or use 
of certain drugs *2 – 6, 13+. In general, it is reported to be an indolent type of leukemia and 
the therapies utilized consist of immunosuppressive drugs that target the associated 
disorder as well. Two main methods were used to determine clonality in T-LGL leukemia 
cases: TCR gene rearrangement analysis or flow cytometric TCR variable beta chain study 
with comparable results *14+. Whether all cases with increased population of peripheral 
blood T cells with T-LGL phenotype by flow cytometry along with determination of clonality 
by either method should be called as T-LGL leukemia remains a question. The required 
duration of the presence of clonal cells longer than six months and the number of circulating 
clonal cells, which is debated as a requirement at this time, may not be sufficient to 
determine the fine line between T-LGL leukemia cases and non-leukemia proliferations in 
our opinion.  It is not clear, whether neutropenia is secondary to clonal T-LGL cells. 
Nevertheless, mortality does not appear to be directly related to presence of these cells 
*15+. It may be solely semantics, but not all clonal proliferations are malignant in nature, like 
LCH that is frequently associated with BRAF mutations, which is currently defined just as a 
neoplastic disorder.  
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The true mechanism of clonal T-LGL development, their target(s) and potential role(s) 
remain largely unknown. The real incidence may be much higher in individuals with 
dysregulated immune system, if routinely examined. The development of clonal T-LGL 
expansions in a certain group of patients with immune dysregulation or stimulation 
conditions, but not in all, and the existence of non-clonal T-LGL proliferations in some need 
further investigation. Progression in long-standing clonal T-LGL proliferations through 
gaining new and/or additional mutations is a possibility. In this regard, presence of STAT3 
mutations may be taken as an indicator for progressive neoplastic state, since 43% of cases 
with Felty syndrome were found to have this mutation [9]. The question stands, whether 
the remainder of those cases without STAT3 mutations represent a more indolent 
neoplastic disease course.  
The great majority of T-LGL leukemia/proliferation cases are in the adult population, less 
than 3% seen in individuals younger than 25 years of age with very rare reporting in children 
*15 – 17+. The series presented here provides additional details to this rather uncommon 
entity due to close and lengthy follow-up in a predominantly pediatric population. None of 
the cases in our series had neutropenia, which is reported in 50% of the patients with T-LGL 
leukemia. The use of immunosuppression has been associated with a relative increase in the 
CD5-dim T cell population size despite decreases in both absolute lymphocyte count and in T 
and B subset values in patients with active underlying disease, which may indicate relative 
resilience of these cells along with continuing immunogenic stimulation. Thus, clonal 
expansion of T-LGL appears to be a dynamic process in our cases reflecting the activity of 
the underlying disease process, including alone or a combination of immunodeficiency, 
autoimmune and alloimmune reactions, infection, inflammation, lymphoproliferation and 
malignancy. As nicely exemplified in the severe combined immunodeficiency case, three 
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separate clonal T-LGL proliferations were associated with maternal engraftment, CMV 
infection following umbilical cord blood transplantation, and acute EBV infection, 
respectively [11].  
In conclusion, the great majority of clonal T-LGL proliferations in young people are likely to 
be reactive in nature, associated with an existing inherited or acquired, persistent or 
temporary immune dysregulation or stimulation state and some may be persistent, longer 
than six months as observed in 9 cases reported here. Our observations emphasize that such 
proliferations can be seen in children and broadens the spectrum of underlying associated 
conditions. Whether the treatment strategy should be modified and the expected clinical 
course or outcome would be affected due to presence of clonal T-LGL proliferations in 
young patients remain unknown. We agree with the theory that clonal T-LGL proliferations 
could be targeting the most prominent immunogenic stressor(s) involved as an effort by the 
immune system to control the process. Studies investigating the function of clonal T-LGL and 
their potential role in the various disease processes are underway. 
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Figure1. Three representative cases. Flow cytometric analysis was made on the CD3-positive 
gated lymphocytes. (A) Case #14 had significant worsening of chronic graft-versus-host 
disease, (B) Case #6 has been treated for active Evans syndrome using several different 
modalities over the years, and (C) Case #11 had a flare of Rosai-Dorfman disease. Giemsa-
stained peripheral blood smears showed several large granular lymphocytes. All showed 
clonal T cell receptor gene rearrangements (Data shown are the GeneScan results of the V-
J1/2 and D1-J1/2 gene rearrangements detected with the Euroclonality/BIOMED-2 TCRB 
tube A and tube C, respectively). 
 
Figure2. A representative case showing CD8 and CD57 staining patterns in CD5-5im-gated T 
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Table 1. Clinical and laboratory findings in reported cases 


















1 M CVID (TACI 
mutation) 





0.7 –  
I 
10 Persistent IVIG 








20.4 Persistent Steroids 












0.1 Persistent UCBT, anti-
CMV Tx 








5.5  Persistent Chemotherapy 








– 0.2  
4.4 – 
F  
13.9 Persistent Steroids, anti-
CMV Tx 





6.4 – I  13.8 Persistent Steroids, 
splenectomy 





3.4 - I 18.6 N/A Steroids 
8 F cITP AI 12.8 16 






12.8 Persistent No therapy 










14.2 Persistent Chemotherapy 
10 M XLP I-ID, LP 28 59 1.93 N/A 28 N/A IVIG 





3.6 - I 5.2  Persistent Steroids 
12 F cGvHD - GT A-ID, ALI 5.1 10 
– 
0.29 
– 0.4  
0.4 - I 5.1 Persistent Steroids 
 
This article is protected by copyright. All rights reserved. 
Abbreviations: M: Male; F: Female; CVID: common variable immune deficiency disorder; TACI: 
Transmembrane Activator and CAML Interactor; cGvHD: chronic graft versus host disease; BL: 
Burkitt lymphoma; SCID: severe combined immunodeficiency; LCH: Langerhans cell histiocytosis: 
pHLH: Primary hemophagocytic lymphohistiocytosis; ES: Evans syndrome; AIHA: Autoimmune 
hemolytic anemia; cITP: Chronic idiopathic thrombocytopenic purpura; HL: Hodgkin lymphoma; 
XLP: X-linked lymphoproliferative disorder; RDD: Rosai-Dorfman disease; GT: Glanzmann 
thrombasthenia; IM: Infectious mononucleosis; EBV: Epstein-Barr virus; SAA: Severe aplastic 
anemia; PB19: Parvovirus B119; PNH: Paroxysmal nocturnal hemoglobinuria; Process: Processes 
involved in the disorder pathogenesis; I-ID: Inherited immune deficiency; LP: Lymphoproliferation; 
A-ID: Acquired immune deficiency; ALI-Allo immunization; INFEC: Infection; AI: Autoimmunity; 
INFLM: Inflammation; MLGN: Malignancy; Age-T-LGL: Age at T-LGL proliferation diagnosis in years; 
T-LGL (%): Percent of T-LGL (CD5-dim T cells) among peripheral blood lymphocytes by flow 
cytometry at diagnosis and last follow up; PB T-LGL: Peripheral blood T-LGL count (x109/L) at 
diagnosis and last follow up; T-LGL Status: Duration of T-LGL presence (in years), current status of 
the T-LGL proliferation by T-LGL percent; D: Decreasing; I: Increasing; F: Fluctuating; S: Stable; Age-
TCR: Age at first TCR gene rearrangement study; TCR Status: Status of the TCR clonotype at the last 
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1.1 – I  11.9  Persistent Steroids, 
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15 M PB19- 
eryhthroid 
aplasia 
INFEC 15.2 9 0.15 N/A  15.2 N/A Blood 
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10 2 (8) V-J2 Polyclonal 
 
This article is protected by copyright. All rights reserved. 
 
 
Abbreviations: M: Male; F: Female; CVID: common variable immune deficiency disorder; TACI: 
Transmembrane Activator and CAML Interactor; cGvHD: chronic graft versus host disease; BL: 
Burkitt lymphoma; SCID: severe combined immunodeficiency; LCH: Langerhans cell histiocytosis: 
pHLH: Primary hemophagocytic lymphohistiocytosis; ES: Evans syndrome; AIHA: Autoimmune 
hemolytic anemia; cITP: Chronic idiopathic thrombocytopenic purpura; HL: Hodgkin lymphoma; 
XLP: X-linked lymphoproliferative disorder; RDD: Rosai-Dorfman disease; GT: Glanzmann 
thrombasthenia; IM: Infectious mononucleosis; EBV: Epstein-Barr virus; SAA: Severe aplastic 
anemia; PB19: Parvovirus B119; PNH: Paroxysmal nocturnal hemoglobinuria; Age-TCR: Age at first 
T Cell Receptor (TCR) gene rearrangement study in years; #TCR tests: Number of TCR tests (time 
between the first and the last TCR tests in months); TCRB: TCR-beta chain gene; TCRG: TCR-gamma 
chain gene 
 
2 cGvHD - BL 20.4 4 (23) D2-J2 Polyclonal 
3 SCID (JAK3 
mutation) 
0.1 12 (27) Various V1-J1/2 and 
D2-J2   
V-J (once) 
4 LCH and HLH 5.5  13 (56) V-J1, D2-J2, D1-J2  Polyclonal 
5 ES (LRBA 
mutation)  
13.9 5 (26) V-J2, D2-J2 Polyclonal 
6 ES 13.8 3 (24) V-J1, D2-J2 Polyclonal 
7 AIHA 18.6 1 D2-J2 V-J 
8 cITP 12.8 2 (9) D1-J2 Polyclonal 
9 HL 14.2 3 (11) V-J2, D1-J2 Polyclonal 
10 XLP 28 1 V-J2, D1-J2 V-J 
11 RDD 5.2  2 (4) V-J2 Polyclonal 
12 cGvHD - GT 5.1 4 (18) V-J1, D2-J2 Polyclonal 
13 IM (EBV 
infection) 
14.7 2 (3) V-J2 Polyclonal 
14 cGvHD, SAA 11.9  4 (21) V-J1, D1-J1, D1-J2 Polyclonal 
15 PB19- eryhthroid 
aplasia 
15.2 1 V-J2 Polyclonal 
16 PNH, SAA 22.9 1  V-J2, D2-J2   Polyclonal 
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